# Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer

> **NCT00426556** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 88 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Everolimus
- **DRUG:** Trastuzumab
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT00426556
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2014-03
- **Final completion:** 2014-03
- **Target enrollment:** 88 (ACTUAL)
- **Last updated:** 2015-12-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00426556

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00426556, "Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00426556. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*